Hypera S.A.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hypera SA is a pharmaceutical company, which engages in the manufacture and distribution of medical and cosmetics products. Its products include foods and sweeteners; over-the-counter medication; prescribed medication; and dermocosmetics. The company was founded on December 1, 2001 and is headquartered in Sao Paulo, Brazil.

Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caused a sharp drop in Hypera's stock over the past five years. The company launched a plan to boost cash flow via reduced receivables and inventory, aiming for long-term profitability but facing short-term earnings challenges.

Hypera: Short-Term Pain For Long-Term Gain

In Reais, I believe there is a 30% upside on Hypera S.A. due to improving margins as the company increases its operation by acquiring other brands and internal development. 75% of the Sell-Side Analysts in Brazil believe that Hypera is a buy and the rest have a neutral rating on the company.

Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio

Banco Bradesco

Banco do Brasil SA

Banco Santander

Companhia Energetica de Minas Gerais

CPFL Energia S.A.

Centrais Eletricas Brasileiras

iShares MSCI Brazil ETF

Itau Unibanco Holding S.A.

Petroleo Brasileiro

Vale S.A.

Four out of thirty-seven Brazilian ADRs scored five out of five on the dividend binomial test and they have an equalweight average 2022 forward dividend yield of 7.6%.

A Brazilian-Focused Dividend Portfolio

News for Hypera S.A. Stock (HYPMY)